From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

• Published in: Circulation research Vol. 118; no. 4; pp. 732 - 749
• Main Authors: Shapiro, Michael D., Fazio, Sergio
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 19.02.2016
• Subjects: Animals; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Atherosclerosis - blood; Atherosclerosis - diagnosis; Atherosclerosis - prevention & control; Biomarkers - blood; Drugs, Investigational - adverse effects; Drugs, Investigational - therapeutic use; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Humans; Hypolipidemic Agents - adverse effects; Hypolipidemic Agents - therapeutic use; Inflammation - blood; Inflammation - diagnosis; Inflammation - drug therapy; Inflammation Mediators - blood; Lipids - blood; Risk Assessment; Risk Factors; Treatment Outcome; cholesterol; cardiovascular diseases; triglycerides; high density lipoprotein cholesterol; low density lipoprotein cholesterol

The introduction of statins ≈30 years ago ushered in the era of lipid lowering as the most effective way to reduce risk of atherosclerotic cardiovascular disease. Nonetheless, residual risk remains high, and statin intolerance is frequently encountered in clinical practice. After a long dry period,...